Daxor (NASDAQ:DXR) Shares Up 0.8% – Should You Buy?

Daxor Co. (NASDAQ:DXR) shares were up 0.8% on Wednesday . The stock traded as high as $7.75 and last traded at $7.69. 24,226 shares were traded during trading, an increase of 221% from the average daily volume of 7,537 shares. The stock had previously closed at $7.63.

Wall Street Analysts Forecast Growth

Separately, Ascendiant Capital Markets boosted their target price on shares of Daxor from $24.50 to $24.75 and gave the company a “buy” rating in a report on Monday, September 9th.

Daxor Stock Performance

The firm has a 50-day moving average of $8.79 and a 200 day moving average of $8.89.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Daxor stock. Keyes Stange & Wooten Wealth Management LLC grew its stake in shares of Daxor Co. (NASDAQ:DXR) by 34.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,612 shares of the company’s stock after purchasing an additional 3,771 shares during the period. Keyes Stange & Wooten Wealth Management LLC owned approximately 0.30% of Daxor worth $126,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 1.34% of the company’s stock.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions.